Industry Groups Push CMS To Pay For Algorithms In Multi-Analyte Tests

The agency’s proposal not to separately pay for the algorithmic analysis that forms the basis of many multi-analyte molecular diagnostic tests misconstrues the nature of the tests, industry groups argue. They call for a final determination by CMS that more truly reflects the value of these assays.

More from Market Access

More from Pink Sheet